Company Reports (Pharmaceutical) Industry Analysis

Discover indepth market information on companies in Pharma & Healthcare. Our catalogue of reports provide detailed data on companies such as Wyeth, AstraZeneca Plc, Illumina Inc, and Johnson & Johnson.

Your filters clear all
None selected
clear

Discounts and Delivery

clear

Price

Change currency
IMS Company Profiles: ASTRAZENECA (IMS00166)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
May 2013£625€742$1,010
IMS Company Profiles: MUNDIPHARMA (IMS00257)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
May 2013£625€742$1,010
IMS Company Profiles: AMGEN (IMS00082)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
May 2013£625€742$1,010
IMS Company Profiles: TEVA (IMS00011)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
May 2013£625€742$1,010
IMS Company Profiles: BAUSCH & LOMB (IMS00032)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
May 2013£625€742$1,010
MEDICAL LABORATORIES - Burgundy & Franche Comté (France) - Industry Report (PLF00596)
Plimsoll's MEDICAL LABORATORIES - Burgundy & Franche Comté (France) analysis is the most definitive and accurate study of the MEDICAL LABORATORIES - Burgundy & Franche Comté (France) sector in 2013. The...
May 2013£505€599$813
MEDICAL LABORATORIES - Bretagne & Pays de la Loire (France) - Industry Report (PLF00595)
Plimsoll's MEDICAL LABORATORIES - Bretagne & Pays de la Loire (France) analysis is the most definitive and accurate study of the MEDICAL LABORATORIES - Bretagne & Pays de...
May 2013£505€599$813
Pharmaceuticals - Industry Report UK (PMS01268)
Plimsoll Publishing's UK Pharmaceuticals Analysis provides a detailed overview of the UK Pharmaceuticals market and delivers a comprehensive individual analysis on the top 1000 companies, including GLAXOSMITHKLINE PLC, GLAXO OPERATIONS...
May 2013£350€415$564
IMS Company Profiles: PFIZER (IMS00158)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
Apr 2013£625€742$1,010
IMS Company Profiles: NOVARTIS (IMS00022)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
Apr 2013£625€742$1,010
IMS Company Profiles: ROCHE (IMS00173)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
Apr 2013£625€742$1,010
IMS Company Profiles: GLAXOSMITHKLINE (IMS00093)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
Apr 2013£625€742$1,010
MITSUBISHI TANABE- Outperform - Invokana: (MPS00068)
Nice to Have A Clean Label, Yet A Long Way To Go Before Gaining Full Confidence!Invokana clean label thrills many on the street rising hopes that Invokana sales could cross $2.5b+ at peak. However we think that CV issues (dose dependent increase in LDL,...
Apr 2013£310€368$500
VERTEX PHARMA - Dependence on Success of its CF Pipeline Risk (MPS00069)
Vertex Pharma"s (VRTX) stock has moved up ~30% in this year mostly based on the positive expectation building on Lumacaftor/KALYDECO (CFTR corrector/ CFTR potentiator, PhIII, homozygous del508 mutation Cystic fibrosis/CF),...
Apr 2013£87€103$140
CADILA HEALTHCARE LTD - Upgrade to Outperform (MPS00066)
We upgrade Cadila Healthcare to Outperform and increase price target from `815 to `1050, as we build into our model forecasts for its high margin / low competition opportunities (Mesalamine...
Apr 2013£87€103$140
RIGEL - SyK Inhibition Not Good Enough (MPS00070)
Limited Market Potential!RIGL/AZN"s Fostamatinib (FosD, syk inhibitor, PhIII) has again disappointed by not demonstrating better or at par efficacy with approved or competing RA drugs. Despite achieving a statistically significant ACR20...
Apr 2013£87€103$140
AstraZeneca - On the verge of a breakdown (MPS00065)
Respiratory portfolio (Symbicort and Pulmicort) threatened by GenericsThe respiratory portfolio of AZN which so far has withstood generics attack, is now giving away. Yesterday"s court ruling invalidating pulmicort respule patent and Teva filing a MAA...
Apr 2013£56€66$90
BIOGEN IDEC - Hold On - After TECFIDERA Array of Approvals Yet to Come! (MPS00067)
Most awaited approval of TECFIDERA (BG - 12, delayed - release capsule of dimethyl fumerate) with a "clean" label should seal Biogen Idec (BIIB)"s supremacy in the MS space. ...
Mar 2013£87€103$140
TRIUS THERAPEUTICS - Partnering or Buy Out equals Upside (MPS00062)
Positive top line data of Tedizolid (oral/IV, 2nd - generation oxazolidinone, PhIII, Acute Bacterial Skin and Skin Structure Infections - ABSSSI; PhII, CAP/HAP/Bacteremia, partnered with Bayer for Asian, LA...
Mar 2013£56€66$90
Astellas, Acofide - Japanese Approval Raises Global Hopes! (MPS00063)
Astellas and Zeria announced today that they received approval for Acofide in Japan (Acotiamide /Z - 338, functional dyspepsia, jointly developed by Astellas and Zeria in Japan). Acofide is the...
Mar 2013£56€66$90
Vendor Assessment: 2012 Top 10 Life Science Software Vendors (IDC13034)
This IDC Health Insights report summarizes the results from a recent study to identify the top 10 software vendors serving the life science market. Initiated in 2010, the 2012 IDC...
Mar 2013£2,795€3,316$4,500
IMS Company Profiles: LILLY (IMS00157)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
Mar 2013£625€742$1,010
IMS Company Profiles: ABBVIE (IMS00270)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
Mar 2013£625€742$1,010
IMS Company Profiles: MERCK & CO (IMS00095)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
Mar 2013£625€742$1,010
IMS Company Profiles: JOHNSON & JOHNSON (IMS00162)
IMS Company Profiles gives a clear picture of the companies' strengths in terms of therapy areas and relevant marketed products as well as the future strategic direction of companies including...
Mar 2013£625€742$1,010